FDA rejects Merck drug, threatening millions in payments to Afferent investors

FDA rejects Merck drug, threatening millions in payments to Afferent investors
·3 min read

Merck promised to pay out $750 million if the Peninsula biotech's drugs passed certain clinical and commercial milestones.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting